These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 14586755

  • 1. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T, Mizutani T, Ishikawa M, Sugiyama K, Hashimoto N.
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [Abstract] [Full Text] [Related]

  • 2. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L, Vitanovics D, Afra D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):394-9. PubMed ID: 15662767
    [Abstract] [Full Text] [Related]

  • 3. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA.
    J Clin Oncol; 1999 Sep 20; 17(9):2762-71. PubMed ID: 10561351
    [Abstract] [Full Text] [Related]

  • 4. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.
    Anticancer Res; 2003 Sep 20; 23(6D):5159-64. PubMed ID: 14981983
    [Abstract] [Full Text] [Related]

  • 5. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S.
    Ann Oncol; 2001 Feb 20; 12(2):259-66. PubMed ID: 11300335
    [Abstract] [Full Text] [Related]

  • 6. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC, Tsao-Wei DD.
    Cancer; 2004 Mar 15; 100(6):1213-20. PubMed ID: 15022289
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE.
    Neuro Oncol; 2002 Jan 15; 4(1):39-43. PubMed ID: 11772431
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F.
    J Clin Oncol; 2001 May 01; 19(9):2449-55. PubMed ID: 11331324
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
    Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K, Peragut JC, Martin PM, Grisoli F.
    Cancer; 2004 May 15; 100(10):2208-14. PubMed ID: 15139066
    [Abstract] [Full Text] [Related]

  • 10. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
    Chamberlain MC, Tsao-Wei DD, Groshen S.
    Cancer; 2006 Jan 01; 106(1):172-9. PubMed ID: 16323194
    [Abstract] [Full Text] [Related]

  • 11. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M.
    J Clin Oncol; 2004 Dec 01; 22(23):4779-86. PubMed ID: 15570079
    [Abstract] [Full Text] [Related]

  • 12. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
    Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A.
    Cancer Invest; 2008 Dec 01; 26(3):269-77. PubMed ID: 18317968
    [Abstract] [Full Text] [Related]

  • 13. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B.
    Eur J Cancer; 2009 Jan 01; 45(1):146-53. PubMed ID: 18945611
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
    Conti A, Pontoriero A, Arpa D, Siragusa C, Tomasello C, Romanelli P, Cardali S, Granata F, De Renzis C, Tomasello F.
    Acta Neurochir (Wien); 2012 Feb 01; 154(2):203-9. PubMed ID: 21984132
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long term experience in high grade glial tumors with temozolomide.
    Demirci U, Buyukberber S, Coskun U, Akmansu M, Yaman E, Baykara M, Yamac D, Uner A, Benekli M.
    J BUON; 2012 Feb 01; 17(2):357-62. PubMed ID: 22740218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.